Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Treatment of hypertriglyceridemia.

Capell WH, Eckel RH.

Curr Diab Rep. 2006 Jun;6(3):230-40. Review.

PMID:
16898578
2.

Treatment of hypertriglyceridemia: a review of current options.

Vrablík M, Češka R.

Physiol Res. 2015;64 Suppl 3:S331-40. Review.

3.

The triglyceride connection in atherosclerosis.

Geurian K, Pinson JB, Weart CW.

Ann Pharmacother. 1992 Sep;26(9):1109-17. Review.

PMID:
1421678
4.

Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis.

Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Stalenhoef A.

Best Pract Res Clin Endocrinol Metab. 2014 Jun;28(3):423-37. doi: 10.1016/j.beem.2013.10.002. Epub 2013 Oct 17. Review.

5.

Icosapent ethyl: a review of its use in severe hypertriglyceridemia.

Kim ES, McCormack PL.

Am J Cardiovasc Drugs. 2014 Dec;14(6):471-8. doi: 10.1007/s40256-014-0099-7. Review.

PMID:
25428605
6.

[Idiopathic hypertriglyceridemia].

Kotake H, Oikawa S.

Nihon Rinsho. 2001 Mar;59 Suppl 3:79-87. Review. Japanese. No abstract available.

PMID:
11347174
7.

Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.

Toth PP.

Vasc Health Risk Manag. 2016 May 6;12:171-83. doi: 10.2147/VHRM.S104369. eCollection 2016. Review.

8.

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome.

Grundy SM.

Am J Cardiol. 1999 May 13;83(9B):25F-29F. Review.

PMID:
10357572
9.

Novel therapeutics in hypertriglyceridemia.

Gryn SE, Hegele RA.

Curr Opin Lipidol. 2015 Dec;26(6):484-91. doi: 10.1097/MOL.0000000000000231. Review.

PMID:
26780002
10.

Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.

Vega GL, Grundy SM.

Am J Cardiol. 1998 Feb 26;81(4A):36B-42B. Review.

PMID:
9526812
11.

Does hypertriglyceridemia increase risk for CAD? Growing evidence suggests it plays a role.

Coughlan BJ, Sorrentino MJ.

Postgrad Med. 2000 Dec;108(7):77-84. Review.

PMID:
11126144
12.

Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?

Dallinga-Thie GM, Kroon J, Borén J, Chapman MJ.

Curr Cardiol Rep. 2016 Jul;18(7):67. doi: 10.1007/s11886-016-0745-6. Review.

13.

Current perspectives on the management of hypertriglyceridemia.

Miller M.

Am Heart J. 2000 Aug;140(2):232-40. Review.

PMID:
10925336
14.

Triglycerides and coronary risk.

Gaziano JM.

Curr Cardiol Rep. 1999 Jul;1(2):125-30. Review.

PMID:
10980831
15.

Hypertriglyceridemia: the importance of identifying patients at risk.

Kushner PA, Cobble ME.

Postgrad Med. 2016 Nov;128(8):848-858. Epub 2016 Oct 12. Review.

PMID:
27710158
16.

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor.

Tenenbaum A, Klempfner R, Fisman EZ.

Cardiovasc Diabetol. 2014 Dec 4;13:159. doi: 10.1186/s12933-014-0159-y. Review.

17.

The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.

Backes J, Anzalone D, Hilleman D, Catini J.

Lipids Health Dis. 2016 Jul 22;15(1):118. doi: 10.1186/s12944-016-0286-4. Review.

18.

Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia.

Patel AA, Budoff MJ.

Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):145-9. doi: 10.1097/MED.0000000000000233. Review.

PMID:
26825470
19.

Treatment of primary hypertriglyceridemia states--General approach and the role of extracorporeal methods.

Stefanutti C, Julius U.

Atheroscler Suppl. 2015 May;18:85-94. doi: 10.1016/j.atherosclerosissup.2015.02.017. Review.

PMID:
25936310
20.

Emergent triglyceride-lowering therapy for hypertriglyceridemic pancreatitis.

He W, Lu N.

Hepatogastroenterology. 2015 Mar-Apr;62(138):429-34. Review.

PMID:
25916076

Supplemental Content

Support Center